A Quote by Alex Berenson

Would-be drug companies must either produce medicines that stand up to federal scrutiny, demonstrate that their data has value to other companies, or go out of business. — © Alex Berenson
Would-be drug companies must either produce medicines that stand up to federal scrutiny, demonstrate that their data has value to other companies, or go out of business.
I think that we can all learn from what smart companies are doing. My objective is to demonstrate what's possible, even during tough economic times. This is a period of great business dislocation, but that means it's also the time to try new things. This will be a challenge for existing companies. But the behaviors of smart companies can be learned.
When screening engineers from other companies, its smart to value engineers from great companies more than those from mediocre companies.
Most companies don't want their data co-mingled with other customers. Small companies will tolerate it.
Go out and collect data and, instead of having the answer, just look at the data and see if the data tells you anything. When we're allowed to do this with companies, it's almost magical.
Basically, the UBR is a relic of an earlier vision for UDDI. The original vision for UDDI was as a standard that would help companies conduct business with each other in an automated fashion. The idea was that companies could publish how they wanted to interact, and other companies could find that information and use it to establish a relationship.
While I support granting drug companies patents to recover their investment and encourage innovation, companies that take advantage of this goodwill to build a monopoly must be stopped.
Insurance companies, drug companies are going to have to be ponying up, partly because right now they're receiving huge subsidies.
The vast majority of companies don't go public and mint dozens of millionaires. And most companies don't go around doling out stock options; private companies tend to be very tight about ownership.
Democrats believe we must have comprehensive health care reform that includes giving the federal government authority to negotiate lower prices with drug companies.
One problem I have with drug companies is that they don't make all their data public.
I think you have to learn that there's a company behind every stock, and that there's only one real reason why stocks go up. Companies go from doing poorly to doing well or small companies grow to large companies.
I'm never gonna owe money because every time I get a dollar, I put it into another business, whether it's to buy goods or develop other companies. You don't have money; you have companies. That's one business model. That's mine. And I only associate with other people that are putting up their own money, 'cause they're the only ones that can relate.
When I was in the Maine Senate and proposed Maine RX - a plan to lower prescription drug costs by forcing the pharmaceutical companies to negotiate - I was told by many people that it was too big an idea, and we couldn't overcome opposition from the drug companies.
My primary early interest was in marketing and my aim was to improve its theories, methods and tools. Early on I pressed companies to adopt a consumer orientation and to be in the value creation business. I didn't pay much attention to the social responsibilities of business until later. Now I am pressing companies to address the triple bottom line: people, the planet, and profits. I found that companies were too much into short term profit maximization and they needed to invest more in sustainability thinking.
Companies are actually much better than governments and other bureaucracies at organizing in a holistically efficient way the extremely complex path from the examination of molecules all the way to the delivery of medicines to patients. Already in the conception and selection of research projects, companies would anticipate all the challenges down the line that they will need to overcome in order to achieve actual health impact. Bureaucratic organizations, by contrast, are notoriously bad at this sort of optimizing.
Unfortunately, bureaucratic problems at the federal level are causing many other small Washington companies to be denied federal funding that would help transfer their ideas from their laboratories into our homes and hospitals.
This site uses cookies to ensure you get the best experience. More info...
Got it!